AAPG Q4 2016 Earnings Report — Ascentage Pharma Group International Revenue & Financial Results | Market Cap Arena

Ascentage Pharma Group InternationalAAPG

Q4 2016 Earnings

Reported December 31, 2016

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	Q4 2016	Q3 2016	Q4 2015	QoQ Change	YoY Change
Revenue	$560.1K	—	—	—	—
Op. Income	-$8M	—	—	—	—
Gross Margin	96.6%	—	—	—	—
Net Margin	-1406.5%	—	—	—	—
EPS (Diluted)	$-0.61	—	—	—	—
Free Cash Flow	-$4M	—	—	—	—

Income Statement

Item	Amount
REVENUE	$560.1K
Cost of Revenue	$19.1K
GROSS PROFIT	$541.1K
R&D Expenses	$8M
Selling & Marketing	$0
General & Administrative	$1M
SG&A Expenses	$1M
Other Expenses	$119.0K
Operating Expenses	$9M
Cost & Expenses	$9M
OPERATING INCOME	-$8M
Interest Income	$950
Interest Expense	$238.1K
Other Income/Expenses	$495.6K
INCOME BEFORE TAX	-$8M
Income Tax Expense	$0
Net Income from Continuing Ops	-$8M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	-$8M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	-$8M
D&A	$12.0K
EBIT	-$8M
EBITDA	-$8M
EPS	-$1
EPS Diluted	-$1

Cash Flow Statement

Item	Amount
Net Income	-$8M
Depreciation & Amortization	$12.0K
Stock-Based Compensation	$5M
Deferred Income Tax	$0
Other Non-Cash Items	-$492.5K
Change in Working Capital	$156.9K
OPERATING CASH FLOW	-$3M
Capital Expenditure	-$246.3K
Acquisitions (Net)	$445.4K
Purchases of Investments	$0
Sales/Maturities of Investments	$0
Other Investing Activities	-$11M
NET CASH FROM INVESTING	-$11M
Net Debt Issuance	$0
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	-$42.4K
NET CASH FROM FINANCING	$32M
FREE CASH FLOW	-$4M
Net Change in Cash	$43M